• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Newman Kurt Douglas was granted 9,737 shares (SEC Form 4)

    8/5/25 5:00:04 PM ET
    $MD
    Hospital/Nursing Management
    Health Care
    Get the next $MD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Newman Kurt Douglas

    (Last) (First) (Middle)
    1301 CONCORD TERRACE

    (Street)
    SUNRISE FL 33323

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Pediatrix Medical Group, Inc. [ MD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/01/2025 A(1) 9,737 A $0 9,737 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Restricted shares granted pursuant to Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with annual equity award. Shares will vest on May 8, 2026.
    /s/ Mary Ann E. Moore, Attorney-in-Fact 08/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MD

    DatePrice TargetRatingAnalyst
    12/16/2024Outperform
    Macquarie
    9/26/2024$8.00 → $14.00Hold → Buy
    Jefferies
    6/7/2024$8.00Sell → Hold
    Deutsche Bank
    2/23/2022$32.00 → $31.00Outperform
    Credit Suisse
    12/22/2021$33.00 → $32.00Outperform
    Credit Suisse
    11/4/2021$29.00 → $27.00Market Perform
    SVB Leerink
    9/27/2021$29.00Market Perform
    SVB Leerink
    8/9/2021$30.00 → $32.00Neutral
    Mizuho
    More analyst ratings

    $MD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Invest & Strategy Neeb Don Gregory was granted 81,346 shares (SEC Form 4)

    4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

    8/5/25 5:05:04 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    SEC Form 3 filed by new insider Neeb Don Gregory

    3 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

    8/5/25 5:00:07 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Director Newman Kurt Douglas was granted 9,737 shares (SEC Form 4)

    4 - Pediatrix Medical Group, Inc. (0000893949) (Issuer)

    8/5/25 5:00:04 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    $MD
    SEC Filings

    View All

    Pediatrix Medical Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)

    8/18/25 4:45:29 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    SEC Form 10-Q filed by Pediatrix Medical Group Inc.

    10-Q - Pediatrix Medical Group, Inc. (0000893949) (Filer)

    8/5/25 7:00:49 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Medical Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Pediatrix Medical Group, Inc. (0000893949) (Filer)

    8/5/25 6:50:27 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    $MD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pediatrix Medical Group Announces $250 Million Share Repurchase Program

    Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today announced that its Board of Directors has authorized a share repurchase program of up to $250 million of the Company's outstanding common stock. "In view of our strong cash flow, current and forecasted cash balances and relatively low debt levels, our Board has authorized a $250 million share repurchase program, which we plan to use opportunistically," said Mark S. Ordan, Chair of the Board and Chief Executive Officer. "We will weigh the use of the repurchase program continually against other potential strategic uses of cash to provide the best long-term return to our shareholders and the strongest fu

    8/18/25 4:30:00 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Medical Group Reports Second Quarter Results

    Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.46 per share for the three months ended June 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.53. For the 2025 second quarter, Pediatrix reported the following results: Net revenue of $469 million; Net income of $39 million; and Adjusted EBITDA of $73 million. "Our second quarter operating results exceeded our forecast and reflect continuing strong neonatology patient volumes, stable payor mix, and careful operations management," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical

    8/5/25 6:00:00 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Medical Group 2025 Second Quarter Conference Call/Webcast Scheduled for Tuesday, August 5, 2025

    Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 5, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2025. A detailed press release will be issued the morning of August 5, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre

    7/21/25 7:00:00 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    $MD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Macquarie initiated coverage on Pediatrix Medical Group

    Macquarie initiated coverage of Pediatrix Medical Group with a rating of Outperform

    12/16/24 7:46:05 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Medical Group upgraded by Jefferies with a new price target

    Jefferies upgraded Pediatrix Medical Group from Hold to Buy and set a new price target of $14.00 from $8.00 previously

    9/26/24 7:37:57 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Medical Group upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Pediatrix Medical Group from Sell to Hold and set a new price target of $8.00

    6/7/24 8:14:20 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    $MD
    Leadership Updates

    Live Leadership Updates

    View All

    Pediatrix Board Appoints Kurt D. Newman, M.D. as Independent Director

    Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today announced that its board of directors has appointed Kurt D. Newman, M.D., former President and Chief Executive Officer of Children's National Hospital in Washington, D.C. and Professor Emeritus of Surgery and Pediatrics at George Washington University School of Medicine and Health Sciences, as an independent director, effective July 1, 2025. Dr. Newman, a surgeon and nationally recognized leader in pediatric healthcare and a long-term healthcare executive, served as President and Chief Executive Officer of Children's National Hospital for 12 years, after spending over 25 years there as a pediatric sur

    7/1/25 4:05:00 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Value Creation

    Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex

    1/13/25 6:00:00 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Board Appoints Sylvia Young as Independent Director

    Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu

    5/4/23 4:05:00 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    $MD
    Financials

    Live finance-specific insights

    View All

    Pediatrix Medical Group Reports Second Quarter Results

    Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.46 per share for the three months ended June 30, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.53. For the 2025 second quarter, Pediatrix reported the following results: Net revenue of $469 million; Net income of $39 million; and Adjusted EBITDA of $73 million. "Our second quarter operating results exceeded our forecast and reflect continuing strong neonatology patient volumes, stable payor mix, and careful operations management," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical

    8/5/25 6:00:00 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Medical Group 2025 Second Quarter Conference Call/Webcast Scheduled for Tuesday, August 5, 2025

    Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Tuesday, August 5, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended June 30, 2025. A detailed press release will be issued the morning of August 5, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and childre

    7/21/25 7:00:00 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Pediatrix Medical Group Reports First Quarter Results

    Raises Full Year 2025 Adjusted EBITDA Outlook Range Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.24 per share for the three months ended March 31, 2025. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.33. For the 2025 first quarter, Pediatrix reported the following results: Net revenue of $458 million; Net income of $21 million; and Adjusted EBITDA of $49 million. "Our strong first quarter results reflect same-unit top-line outperformance versus our expectations, continued steady cost management and the successful results of the portfolio restructuring we completed last year. As a result of our strong f

    5/6/25 6:00:00 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    $MD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pediatrix Medical Group Inc.

    SC 13G - Pediatrix Medical Group, Inc. (0000893949) (Subject)

    11/13/24 4:30:24 PM ET
    $MD
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pediatrix Medical Group Inc.

    SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)

    10/31/24 11:54:57 AM ET
    $MD
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G/A filed by Pediatrix Medical Group Inc. (Amendment)

    SC 13G/A - Pediatrix Medical Group, Inc. (0000893949) (Subject)

    6/10/24 12:43:02 PM ET
    $MD
    Hospital/Nursing Management
    Health Care